ArticleJournal of leukocyte biology2012
Cell surface localization and release of the candidate tumor suppressor Ecrg4 from polymorphonuclear cells and monocytes activate macrophages.
Article in Journal of leukocyte biology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 34 citations in OpenAlex.
- Plasma ECRG4 as a novel diagnostic marker for Alzheimer's disease associated with oligodendrocyte dysfunction.American journal of translational research · 2026Article
- Emerging roles of spexin in cardiovascular homeostasis.Frontiers in cardiovascular medicine · 2026Review
- ECRG4 mediates host response to cutaneous infection by regulating neutrophil recruitment and adhesion receptor expression.PloS one · 2024Article
- Esophageal Cancer-Related Gene-4 Contributes to Lipopolysaccharide-Induced Ion Channel Dysfunction in hiPSC-Derived Cardiomyocytes.Journal of inflammation research · 2024Article
- Complex and pleiotropic signaling pathways regulated by the secreted protein augurin.Cell communication and signaling : CCS · 2023Review
- A potential link between aberrant expression of ECRG4 and atrial fibrillation.Frontiers in oncology · 2023Review
- Cardiac Expression of Esophageal Cancer-Related Gene-4 is Regulated by Sp1 and is a Potential Early Target of Doxorubicin-Induced Cardiotoxicity.Cardiovascular toxicology · 2022Article
- The ECRG4 cleavage product augurin binds the endotoxin receptor and influences the innate immune response during otitis media.Frontiers in genetics · 2022Article
- ECRG4 regulates neutrophil recruitment and CD44 expression during the inflammatory response to injury.Science advances · 2020Article
- Potential functions of esophageal cancer-related gene-4 in the cardiovascular system.Frontiers of medicine · 2019Review
- Open reading frame mining identifies a TLR4 binding domain in the primary sequence of ECRG4.Cellular and molecular life sciences : CMLS · 2019Article
- ECRG4: a new potential target in precision medicine.Frontiers of medicine · 2019Review
- Ecrg4 peptide is the ligand of multiple scavenger receptors.Scientific reports · 2018Article
- A short synthetic peptide fragment of human C2ORF40 has therapeutic potential in breast cancer.Oncotarget · 2017Article
- A Potential Role of Esophageal Cancer Related Gene-4 for Atrial Fibrillation.Scientific reports · 2017Article
- Soluble purified recombinant C2ORF40 protein inhibits tumor cell growthOncology letters · 2016Article
- The Orphan C2orf40 Gene is a Neuroimmune Factor in Alzheimer's Disease.JSM Alzheimer's disease and related dementia · 2016Article
- Monitoring Neutrophil-Expressed Cell Surface Esophageal Cancer Related Gene-4 after Severe Burn Injury.Surgical infections · 2015Article
- Soluble purified recombinant C2ORF40 protein inhibits esophageal cancer cell proliferation by inducing cell cycle GOncology letters · 2015Article
- ECRG4 expression in normal rat tissues: expression study and literature review.European journal of histochemistry : EJH · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
We identified fresh human leukocytes as an abundant source of the candidate epithelial tumor suppressor gene, Ecrg4, an epigenetically regulated gene, which unlike other tumor suppressor genes, encodes an orphan-secreted, ligand-like protein. In human cell lines, Ecrg4 gene expression was low, Ecrg4 protein undetectable, and Ecrg4 promoter hypermethylation high (45-90%) and reversible by the methylation inhibitor 5-AzaC. In contrast, Ecrg4 gene expression in fresh, normal human PBMCs and PMNs was 600-800 times higher than in cultured cell lines, methylation of the Ecrg4 promoter was low (<3%), and protein levels were readily detectable in lysates and on the cell surface. Flow cytometry, immunofluorescent staining, and cell surface biotinylation established that full-length, 14-kDa Ecrg4 was localized on PMN and monocyte cell surfaces, establishing that Ecrg4 is a membrane-anchored protein. LPS treatment induced processing and release of Ecrg4, as detected by flow and immunoblotting, whereas an effect of fMLF treatment on Ecrg4 on the PMN cell surface was detected on the polarized R2 subpopulation of cells. This loss of cell surface Ecrg4 was associated with the detection of intact and processed Ecrg4 in the conditioned media of fresh leukocytes and was shown to be associated with the inflammatory response that follows severe, cutaneous burn injury. Furthermore, incubation of macrophages with a soluble Ecrg4-derived peptide increased the P-p65, suggesting that processing of an intact sentinel Ecrg4 on quiescent circulating leukocytes leads to processing from the cell surface following injury and macrophage activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.